WallStSmart

Amazon.com Inc (AMZN)vsPfizer Inc (PFE)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Amazon.com Inc generates 1046% more annual revenue ($716.92B vs $62.58B). PFE leads profitability with a 12.4% profit margin vs 10.8%. AMZN appears more attractively valued with a PEG of 1.98. AMZN earns a higher WallStSmart Score of 59/100 (C).

AMZN

Buy

59

out of 100

Grade: C

Growth: 6.7Profit: 6.5Value: 7.3Quality: 6.5
Piotroski: 3/9Altman Z: 2.33

PFE

Hold

49

out of 100

Grade: D+

Growth: 2.0Profit: 6.5Value: 4.7Quality: 4.8
Piotroski: 3/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AMZNSignificantly Overvalued (-95.3%)

Margin of Safety

-95.3%

Fair Value

$106.26

Current Price

$211.71

$105.45 premium

UndervaluedFair: $106.26Overvalued
PFESignificantly Overvalued (-194.9%)

Margin of Safety

-194.9%

Fair Value

$9.25

Current Price

$27.28

$18.03 premium

UndervaluedFair: $9.25Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AMZN3 strengths · Avg: 9.7/10
Market CapQuality
$2.27T10/10

Mega-cap, among the largest globally

Free Cash FlowQuality
$14.94B10/10

Generating 14.9B in free cash flow

Return on EquityProfitability
22.3%9/10

Every $100 of equity generates 22 in profit

PFE4 strengths · Avg: 8.3/10
Market CapQuality
$153.36B9/10

Large-cap with strong market position

Price/BookValuation
1.8x8/10

Reasonable price relative to book value

Operating MarginProfitability
23.9%8/10

Strong operational efficiency at 23.9%

Free Cash FlowQuality
$4.50B8/10

Generating 4.5B in free cash flow

Areas to Watch

AMZN3 concerns · Avg: 3.7/10
PEG RatioValuation
1.984/10

Expensive relative to growth rate

P/E RatioValuation
29.5x4/10

Moderate valuation

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PFE4 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
13.772/10

Expensive relative to growth rate

Revenue GrowthGrowth
-1.2%2/10

Revenue declined 1.2%

EPS GrowthGrowth
-21.3%2/10

Earnings declined 21.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : AMZN

The strongest argument for AMZN centers on Market Cap, Free Cash Flow, Return on Equity. Revenue growth of 13.6% demonstrates continued momentum.

Bull Case : PFE

The strongest argument for PFE centers on Market Cap, Price/Book, Operating Margin.

Bear Case : AMZN

The primary concerns for AMZN are PEG Ratio, P/E Ratio, Piotroski F-Score.

Bear Case : PFE

The primary concerns for PFE are Piotroski F-Score, PEG Ratio, Revenue Growth.

Key Dynamics to Monitor

AMZN profiles as a value stock while PFE is a declining play — different risk/reward profiles.

AMZN carries more volatility with a beta of 1.42 — expect wider price swings.

AMZN is growing revenue faster at 13.6% — sustainability is the question.

AMZN generates stronger free cash flow (14.9B), providing more financial flexibility.

Bottom Line

AMZN scores higher overall (59/100 vs 49/100) and 13.6% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Amazon.com Inc

CONSUMER CYCLICAL · INTERNET RETAIL · USA

Amazon.com, Inc. is an American multinational technology company which focuses on e-commerce, cloud computing, digital streaming, and artificial intelligence. It is one of the Big Five companies in the U.S. information technology industry, along with Google, Apple, Microsoft, and Facebook. The company has been referred to as one of the most influential economic and cultural forces in the world, as well as the world's most valuable brand.

Visit Website →

Pfizer Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.

Visit Website →

Want to dig deeper into these stocks?